000 01384 a2200409 4500
005 20250512014629.0
264 0 _c19890713
008 198907s 0 0 eng d
022 _a0143-3636
024 7 _a10.1097/00006231-198903000-00004
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aCrowther, M E
245 0 0 _aTherapeutic considerations in the use of intraperitoneal radiolabelled monoclonal antibodies in ovarian carcinoma.
_h[electronic resource]
260 _bNuclear medicine communications
_cMar 1989
300 _a149-59 p.
_bdigital
500 _aPublication Type: Journal Article
650 0 4 _aAdult
650 0 4 _aAged
650 0 4 _aAntibodies, Monoclonal
_xadverse effects
650 0 4 _aCatheters, Indwelling
_xadverse effects
650 0 4 _aFemale
650 0 4 _aHumans
650 0 4 _aIntestinal Diseases
_xetiology
650 0 4 _aIodine Radioisotopes
650 0 4 _aMiddle Aged
650 0 4 _aNeoplasm Staging
650 0 4 _aOvarian Neoplasms
_xpathology
650 0 4 _aPeritoneal Neoplasms
_xpathology
700 1 _aWard, B G
700 1 _aGranowska, M
700 1 _aMather, S
700 1 _aBritton, K E
700 1 _aShepherd, J H
700 1 _aSlevin, M L
773 0 _tNuclear medicine communications
_gvol. 10
_gno. 3
_gp. 149-59
856 4 0 _uhttps://doi.org/10.1097/00006231-198903000-00004
_zAvailable from publisher's website
999 _c2731975
_d2731975